Search research articles
Contact Us
Filters
Showing results (51-60 of 321) with videos related to
Page
of 33
Sort By:
The Oncologist
|
January 25, 2013
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents
Kyle W Robinson, Alan B Sandler
Current Problems in Cancer
|
May 15, 1998
Treatment of advanced (stages III and IV) non-small-cell lung cancer
C J Sweeney, A B Sandler
Lung
|
January 1, 1992
Lung cancer: a review of current therapeutic modalities
A B Sandler, A C Buzaid
Lung Cancer (Amsterdam, Netherlands)
|
July 18, 2003
The importance of the eicosanoid pathway in lung cancer
Janessa J Laskin, Alan B Sandler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2006
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials
David M Dilts, Alan B Sandler
Seminars in Oncology
|
June 5, 2004
COX-2 inhibition and lung cancer
Alan B Sandler, Steven M Dubinett
Cancer Science
|
September 26, 2007
Inhibition of angiogenesis in the treatment of non-small cell lung cancer
Vicki L Keedy, Alan B Sandler
Cancer Treatment and Research
|
February 28, 2001
The epidemiology of lung cancer
M D Williams, A B Sandler
Expert Opinion on Drug Safety
|
March 1, 2006
The safety of bevacizumab
Rachel E Sanborn, Alan B Sandler
Sovetskaia Meditsina
|
January 1, 1981
[Severe medicamentous disease induced by aminazine and barbiturates]
B B Sandler, A D Shersneva
Page
of 33
Search research articles
Search
Showing results (51-60 of 321) with videos related to
Sort By:
Page
of 33
The Oncologist
|
January 25, 2013
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents
Kyle W Robinson, Alan B Sandler
Current Problems in Cancer
|
May 15, 1998
Treatment of advanced (stages III and IV) non-small-cell lung cancer
C J Sweeney, A B Sandler
Lung
|
January 1, 1992
Lung cancer: a review of current therapeutic modalities
A B Sandler, A C Buzaid
Lung Cancer (Amsterdam, Netherlands)
|
July 18, 2003
The importance of the eicosanoid pathway in lung cancer
Janessa J Laskin, Alan B Sandler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2006
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials
David M Dilts, Alan B Sandler
Seminars in Oncology
|
June 5, 2004
COX-2 inhibition and lung cancer
Alan B Sandler, Steven M Dubinett
Cancer Science
|
September 26, 2007
Inhibition of angiogenesis in the treatment of non-small cell lung cancer
Vicki L Keedy, Alan B Sandler
Cancer Treatment and Research
|
February 28, 2001
The epidemiology of lung cancer
M D Williams, A B Sandler
Expert Opinion on Drug Safety
|
March 1, 2006
The safety of bevacizumab
Rachel E Sanborn, Alan B Sandler
Sovetskaia Meditsina
|
January 1, 1981
[Severe medicamentous disease induced by aminazine and barbiturates]
B B Sandler, A D Shersneva
Page
of 33